COMP <GO>
OSCR vs JNJ // PIOTROSKI F-SCORE QUALITY
Oscar Health Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: OSCR 3
— JNJ 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $30.37 (-1.36%) • MKT CAP: $9.50B
piotroski-score
6/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OSCR VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OSCR | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 11.51% | 2.97% | +8.54 | OSCR | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 39.00% | 6.00% | +33.00 | OSCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | OSCR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 60.4 | -18.87 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.08 | -0.11 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 23.0x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.50B | $662.49B | -$652.99B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OSCR REV | JNJ REV | OSCR GROSS % | JNJ GROSS % | OSCR FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.6M | $94.19B | 44.0% | 67.9% | $1.09B | $19.70B |
| FY 2024 | $20.6M | $88.82B | 44.0% | 69.1% | $977.3M | $19.84B |
| FY 2023 | $21.4M | $85.16B | 44.0% | 44.0% | -$273.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OSCR // BETA 0.97
JNJ // BETA 1.08